RxDoctor Payments DataLook up a doctor →

Brian Lingerfelt, MD

Hematology & Oncology · Charleston, SCNPI 1942418744

Payments from drug & device makers

$1,071,412in general payments, 2019–2025

Across 868 payments — averaging $1234.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$430K
  • E.r. Squibb & Sons, L.L.C.$377K
  • Genentech, Inc.$134K
  • Eli Lilly$73K
  • Pfizer$18K
  • Jazz Pharmaceuticals Inc.$14K
  • plus $25K from 54 others
$12,961in research payments, 2019–2025

Across 4 payments — averaging $3240.25 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • E.r. Squibb & Sons, L.L.C.$10K
  • Eli Lilly$3K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Merck97$429,618
E.r. Squibb & Sons, L.L.C.102$376,997
Genentech, Inc.24$134,135
Eli Lilly6$73,040
Pfizer37$17,774
Jazz Pharmaceuticals Inc.21$13,981
Ipsen Biopharmaceuticals, Inc6$7,720
Ipsen Bioscience Inc.6$4,428
AstraZeneca(2 entities)51$1,386
Sanofi US Services Inc.1$1,125
Novartis52$1,047
Johnson & Johnson42$786
Sanofi23$620
Bristol Myers Squibb28$537
Genentech USA, Inc.22$475
Gilead(2 entities)22$471
Mckesson Specialty Care Distribution, LLC7$466
Amgen23$459
Incyte Corporation20$398
Regeneron Healthcare Solutions, Inc.22$393
GSK18$366
Daiichi Sankyo Inc.14$339
Takeda Pharmaceuticals U.S.A., Inc.13$323
Astellas Pharma US Inc12$295
Array Biopharma Inc17$293
AbbVie11$232
Rigel Pharmaceuticals, Inc.9$214
Beigene USA, Inc.11$212
Lilly USA, LLC10$206
Seagen Inc.6$179
Foundation Medicine, Inc.1$175
Acrotech Biopharma Inc.7$171
Eisai Inc.8$152
Sobi, Inc7$127
AVEO Pharmaceuticals, Inc.5$127
Sanofi-aventis U.S. LLC2$117
Karyopharm Therapeutics Inc.6$113
Puma Biotechnology, Inc.6$106
Alnylam Pharmaceuticals Inc.4$101
Stemline Therapeutics Inc.4$99
Pharmacyclics LLC, An Abbvie Company5$92
Boehringer Ingelheim4$86
Novocure Inc.3$84
Adaptive Biotechnologies Corporation3$81
Bayer5$79
Secura Bio, Inc.5$78
Taiho Oncology, Inc.4$77
Dova Pharmaceuticals4$73
G1 Therapeutics, Inc.3$62
Tersera Therapeutics LLC3$59
Pharmaessentia USA Corporation2$54
ADC Therapeutics America, Inc.3$51
Lexicon Pharmaceuticals, Inc.3$49
Mylan Institutional Inc.3$46
EMD Serono, Inc.3$46
AMAG Pharmaceuticals, Inc.2$38
Pharmacosmos Therapeutics Inc.2$35
Deciphera Pharmaceuticals Inc.1$34
Teva Pharmaceuticals USA, Inc.2$32
Clovis Oncology, Inc.2$29

How this compares

$1,071,412 in reported general payments places this provider in the 90th percentile of 166 hematology & oncology providers in South Carolina.

See all hematology & oncology providers in South Carolina →

Medicare billing

Part B allowed, 2024
$93,859
Medicare patients
364
Services billed
829

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Charleston

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →